Surgalign Beset by Problems with Legacy Business

Surgalign's logo

Surgalign reported 2Q21 orthopedic revenue of $24.8 million, +20.9% vs. 2Q20. However, the company declined -24.2% compared to 2Q19. Quality and regulatory issues that impacted product availability offset the gains from the return of elective procedures. Leadership described the problem as "continued quality issues in our global supply chain...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us